Hansa Medical applies for stock exchange listing

Important information
The information in this press release is not directed at persons located in
Australia, Canada, Hong Kong, Japan, New Zealand, the Republic of Korea,
Singapore, South Africa, Switzerland, the United States or any other country
where the offer or sale of subscription rights, interim shares or new shares is
not permitted. The information may not be published or distributed, directly or
indirectly, in or into, any of the aforementioned countries or any other country
where such action is wholly or partially subject to legal restrictions or where
such action would require additional prospectuses, other offer documentation,
registrations or other actions in addition to what follows from Swedish law. Nor
may the information be forwarded, reproduced or disclosed in such a manner that
contravenes such restrictions or gives cause to such requirements. Failure to
comply with these instructions may result in a violation of the United States
Securities Act of 1933, as amended (“Securities Act”) or laws applicable in
other jurisdictions.

The information in this press release does not contain or constitute an
invitation or an offer to acquire, sell, subscribe for or otherwise trade in
shares, subscription rights or other securities in Hansa Medical AB. No
subscription rights, interim shares or new shares will be registered under the
Securities Act or in accordance with any other rules or regulations in any other
country than Sweden and may not be transferred or offered for sale in the United
States or any country where such transfer or offer may be prohibited, or to
persons resident in any such country or on account of such persons, other than
pursuant to an exemption from, or in a transaction not subject to, the
registration requirements of the Securities Act or similar legislation in
another country, respectively.

Hansa Medical AB (publ) applies for admission to trading on Nasdaq Stockholm’s
main market.

Hansa Medical has previously announced that it has submitted a preliminary
application to have its shares admitted to trading on the Nasdaq Stockholm main
market. The company has now submitted a final application with planned first day
for trading on November 2, 2015, which would mean that the last day for trading
on First North Premier would be October 30, 2015. The prospectus written due to
the application is presently planned to be published on or around October 26,
2015. The stock exchange listing is not combined with any issue, sale or other
offering to the market.

The information in this press release is disclosed pursuant to the Securities
Markets Act or the Financial Instruments Trading Act. The information was
released for public disclosure on October 13, 2015 at 08.00 CET.
For further information, please contact:
Hansa Medical AB
Göran Arvidson, CEO
Mobile: 46 70-390 85 30
E-mail: goran.arvidson@hansamedical.com
www.hansamedical.com
About Hansa Medical AB
Hansa Medical is a biopharmaceutical company focused
on novel immunomodulatory enzymes. Lead project IdeS is an antibody-degrading
enzyme in clinical development, with potential use in transplantation and rare
autoimmune diseases. Other projects include HBP (a market introduced diagnostic
marker for severe sepsis) and EndoS (an antibody-modulating bacterial enzyme in
pre-clinical development). The company is based in Lund, Sweden. Hansa Medical's
share (HMED) is listed on Nasdaq First North in Stockholm with Remium Nordic AB
as Certified Adviser.